HK1123725A1 - Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (vr1) receptors - Google Patents

Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (vr1) receptors

Info

Publication number
HK1123725A1
HK1123725A1 HK09103120.8A HK09103120A HK1123725A1 HK 1123725 A1 HK1123725 A1 HK 1123725A1 HK 09103120 A HK09103120 A HK 09103120A HK 1123725 A1 HK1123725 A1 HK 1123725A1
Authority
HK
Hong Kong
Prior art keywords
receptors
preparation
inhibit vanilloid
ureas
indazolyl
Prior art date
Application number
HK09103120.8A
Other languages
English (en)
Inventor
Kirill A Lukin
Hsu Margaret Chi-Ping
Dilinie P Fernando
Brian J Kotecki
Marvin R Leanna
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of HK1123725A1 publication Critical patent/HK1123725A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
HK09103120.8A 2006-04-14 2009-04-01 Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (vr1) receptors HK1123725A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79209906P 2006-04-14 2006-04-14
PCT/US2007/066605 WO2007121339A2 (fr) 2006-04-14 2007-04-13 Procede de preparation d'indazolyl urees qui inhibent les recepteurs vanilloides de sous-type 1 (vr1)

Publications (1)

Publication Number Publication Date
HK1123725A1 true HK1123725A1 (en) 2009-06-26

Family

ID=38610399

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09103120.8A HK1123725A1 (en) 2006-04-14 2009-04-01 Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (vr1) receptors

Country Status (21)

Country Link
US (2) US7847104B2 (fr)
EP (1) EP2012779B1 (fr)
JP (1) JP2009533474A (fr)
KR (2) KR101118932B1 (fr)
CN (4) CN102140081A (fr)
AU (1) AU2007238019B2 (fr)
BR (1) BRPI0709963A2 (fr)
CA (1) CA2647261A1 (fr)
CR (1) CR10357A (fr)
EC (1) ECSP088878A (fr)
ES (1) ES2385404T3 (fr)
HK (1) HK1123725A1 (fr)
MX (1) MX2008013205A (fr)
MY (1) MY145334A (fr)
NO (1) NO20084698L (fr)
NZ (1) NZ571705A (fr)
RU (1) RU2446161C2 (fr)
TW (1) TW200815362A (fr)
UA (1) UA94100C2 (fr)
WO (1) WO2007121339A2 (fr)
ZA (1) ZA200808596B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2439705T3 (es) * 2007-10-25 2014-01-24 Genentech, Inc. Proceso para la preparación de compuestos de tienopirimidina
CN102036969A (zh) 2008-03-20 2011-04-27 雅培制药有限公司 制造作为trpv1拮抗剂的中枢神经系统药剂的方法
CN102070420B (zh) * 2011-01-04 2013-12-18 常州大学 一种2-溴-6-氟苯甲醛的制备方法
US20140275505A1 (en) * 2013-03-13 2014-09-18 Dow Agrosciences Llc Process for the preparation of certain triaryl rhamnose carbamates
MX2019000512A (es) 2016-07-12 2019-05-02 Bayer Cropscience Ag Compuestos biciclicos como plaguicidas.
CN106977535A (zh) * 2017-04-28 2017-07-25 大连联化化学有限公司 一种合成2‑氰基3‑氟苯硼酸工艺

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054833A (fr) * 1963-08-09
DE2458965C3 (de) * 1974-12-13 1979-10-11 Bayer Ag, 5090 Leverkusen 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
WO1995006044A1 (fr) 1993-08-20 1995-03-02 Smithkline Beecham Plc Derives d'amide et d'uree en tant qu'antagonistes du recepteur 5ht1d
JP5039268B2 (ja) * 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
CA2480497A1 (fr) 2002-04-26 2003-11-06 Pharmacia & Upjohn Company Derives pyraziniques substitues
NZ543614A (en) * 2003-05-22 2009-09-25 Abbott Lab Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US7375126B2 (en) * 2003-06-12 2008-05-20 Abbott Laboratories Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2005030121A2 (fr) * 2003-06-30 2005-04-07 Hif Bio, Inc. Composes, compositions et procedes
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
WO2006020070A2 (fr) * 2004-07-16 2006-02-23 Teva Pharmaceutical Industries, Ltd. Uraciles indanylamino et leur utilisation en tant qu'agents antioxydants et neuroprotecteurs
US20070021450A1 (en) * 2004-07-16 2007-01-25 Benjamin Sklarz Indanylamino uracils and their use as antioxidants and neuroprotectants
US8071609B2 (en) * 2005-08-11 2011-12-06 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
US20070161645A1 (en) * 2005-11-02 2007-07-12 Targegen, Inc. Thiazole inhibitors targeting resistant kinase mutations
KR20080072753A (ko) * 2005-11-30 2008-08-06 에프. 호프만-라 로슈 아게 3-아미노-1-아릴프로필 인돌 및 아자-치환된 인돌

Also Published As

Publication number Publication date
EP2012779A2 (fr) 2009-01-14
US20070244178A1 (en) 2007-10-18
US7847104B2 (en) 2010-12-07
UA94100C2 (ru) 2011-04-11
CR10357A (es) 2008-12-11
US20110040102A1 (en) 2011-02-17
AU2007238019B2 (en) 2013-03-14
ECSP088878A (es) 2008-12-30
KR20110017464A (ko) 2011-02-21
JP2009533474A (ja) 2009-09-17
EP2012779A4 (fr) 2010-11-24
AU2007238019A1 (en) 2007-10-25
EP2012779B1 (fr) 2012-05-16
CN102321025A (zh) 2012-01-18
RU2008144961A (ru) 2010-05-20
BRPI0709963A2 (pt) 2011-08-02
MX2008013205A (es) 2008-10-22
MY145334A (en) 2012-01-31
ZA200808596B (en) 2010-03-31
NO20084698L (no) 2008-11-07
RU2446161C2 (ru) 2012-03-27
WO2007121339A3 (fr) 2008-10-02
NZ571705A (en) 2012-03-30
CN102775350A (zh) 2012-11-14
KR20090003335A (ko) 2009-01-09
ES2385404T3 (es) 2012-07-24
CN101466374A (zh) 2009-06-24
KR101118932B1 (ko) 2012-02-27
CA2647261A1 (fr) 2007-10-25
CN101466374B (zh) 2012-03-21
CN102140081A (zh) 2011-08-03
US8519186B2 (en) 2013-08-27
TW200815362A (en) 2008-04-01
WO2007121339A2 (fr) 2007-10-25

Similar Documents

Publication Publication Date Title
ZA200808691B (en) Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
IL183321A0 (en) Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof
HK1157757A1 (zh) 製備環巴胺類似物化合物的方法
HK1123725A1 (en) Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (vr1) receptors
DK3872058T3 (en) Process for the preparation of 2,3,3,3 tetrahydrofluoropropene
PL1806330T3 (pl) Sposób wytwarzania 1-butenu z technicznych mieszanin węglowodorów C<sub>4</sub>
ZA200707614B (en) Process for the polymerizatio of olefins
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
ZA200903533B (en) Process for the preparation of rosuvastatin
IL187208A0 (en) Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
PL2222678T3 (pl) Sposoby wytwarzania związków morfinanowych (+)-'nal'
IL191753A0 (en) Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors
MX2010008713A (es) Derivados de 5,6-bisaril-2-piridina-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de la urotensina ii.
IL187426A0 (en) Piperidin-4-yl-amide derivatives and their use as sst receptor subtype 5 antagonists
EG25547A (en) Process for the preparation of amines
HK1144682A1 (en) Process for the preparation of alkyl 3,3-dialkoxypropionates 33-
WO2009076408A3 (fr) Dérivés de 3-carboxypropyl-aminotétraline et composés associés en tant qu'antagonistes du récepteurs mu-opioïde
GB2441840B (en) Process for the synthesis of arylfluorenes and analogues thereof
IL191052A0 (en) Process for the preparation of tamsulosin and related compounds
EP2084168A4 (fr) Processus pour la préparation de composés dialkyldithiophosphiniques hautement purifiés
ZA200704722B (en) Process for the preparation of lower olefins from heavy wax
HK1128287A1 (en) Process for the preparation of tryptase inhibitors
ZA200804778B (en) New process for the preparation of esomeprazole non-salt form
IL177353A0 (en) Process for the preparation of aq4n
ZA200607540B (en) Process for the preparation of substituted triazole compounds